Sitemap

About Cellceutix

• About Cellceutix.
• Privacy Statement.
• Terms of Use Agreement.

• From the desk of our CEO (2/17/2010).
• The Best Is Yet To Come (2/27/2011).

Investors

• Contact Us.
• SEC Filings.
• Stay in the Know.
• Stock Information.
• Talk to Us.

Kevetrin

• Cellceutix Posters Presented at American Association for Cancer Research.

Management

• Our Team.

Product Candidates

• Kevetrin™ - Our lead compound.
• KM 133 - Psoriasis Compound.
• KM 391 - Autism Compound.
• KM-133 Summary.
• Product Pipeline.

The News

• Leo Ehrlich - CFO - featured in interview with CEOCFO.
• Breast Cancer Awareness Month Draws Investors Too.
• Cellceutix Announces Acquisition of New Compound.
• Cellceutix Aquires New Compound for Autism.
• Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com.
• Cellceutix Corporation has acquired the rights to the blood pressure compound KM 732.
• Cellceutix Eyeing A $5B Annual Market With Potential Caner Research Breakthrough.
• Cellceutix Files Patent Application For Its Cancer Compound.
• Cellceutix Files Patent Application For Its Cancer Compound.
• Cellceutix makes strides with Kevetrin cancer drug.
• Cellceutix Management Outlines Enormous Potential in Exclusive BiotechStockTrader.com Interview.
• Cellceutix Matriculates to Harvard.
• Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug.
• Cellceutix of Wilmington Mass completed a $400,000 9 percent secured convertible debenture finan.
• Cellceutix signs agreement with Girindus America.
• CTIX and CTIC: A Demonstration in Biotech Stock Ticker Confusion.
• Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product.
• IFCR in pact for collaborative research.
• Interview With CEO Of Cellceutix Corporation: Leo Ehrlich .
• Interview with George Evans at SmallCapVoice.com.
• Stu Taylor on Business, April 10, 2010 show.
• Syracuse basketball coach Jim Boeheim keeps working for cancer breakthrough.
• The Salem News: Autism drug tested on rats.

• Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board.
• Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation.
• Cellceutix "Back in the Game" With cGMP Manufacturing Completed on New Cancer Drug.
• Cellceutix Abstract Accepted by AACR.
• Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug.
• Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties.
• Cellceutix Announces Departure of George W. Evans as CEO.
• Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010.
• Cellceutix Announces Positive Results With Autism Compound.
• Cellceutix Announces Settlement With Former CEO.
• Cellceutix Announces that it has Signed Confidential Disclosure Agreement for its Autism Drug with L.
• Cellceutix Anti-Cancer Breakthrough Selected for Poster Presentation at AACR.
• Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2.
• Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug.
• Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent.
• Cellceutix at AACR.
• Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain.
• Cellceutix cancer compound: Crunching the numbers.
• Cellceutix Cancer Drug Kevetrin Shows No Genotoxicity in Study.
• Cellceutix Cancer Drug Trumps Competitors.
• Cellceutix Cancer Drug, Kevetrin, Shows Increased Levels of p21; Biomarker for Cancer Trials.
• Cellceutix Cancer Trial Enrollment Planned for August 2012.
• Cellceutix Ceo Appears On Stu Taylor On Business - Cancer And Autism Compounds Are Discussed.
• Cellceutix CEO States - Full Speed Ahead.
• Cellceutix CEO-and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug-Company .
• Cellceutix CFO Discusses Autism Drug - Kevetrin and Company Progressions with CEOCFO Interviews and.
• Cellceutix Closing in on Human Trials with Kevetrin for Drug-Resistant Cancers.
• Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Req by FDA.
• Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug.
• Cellceutix Compound Shows Significant Effect On Psoriasis.
• Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested.
• Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound.
• Cellceutix Discovers Drug Activates - Guardian Angel p53 - in Fight Against Leukemia.
• Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center.
• Cellceutix Featured on Cover of Prominent Business Journal.
• Cellceutix Files Amended IND With FDA for Its Novel p53 "Guardian Angel" Anti-Cancer Drug .
• Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer C.
• Cellceutix Files Investigational New Drug Application (IND) with FDA.
• Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug .
• Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site.
• Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoria.
• Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the Guardian Angel of the Human.
• Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials.
• Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment.
• Cellceutix Novel Anti-Cancer Compound Kevetrin(TM) Presented at AACR.
• Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at.
• Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR M.
• Cellceutix Poster Presented at American Association for Cancer Research.
• Cellceutix Presents Poster Session at AACR Important New Data on Kevetrin in Resistant Lung Can.
• Cellceutix Provides Updates on IND for Cancer Drug - Initiates Collaborative Agreement With Pioneer.
• Cellceutix Provides Updates on Kevetrin - Cellceutixs Novel Anti-Cancer Therapy.
• Cellceutix Receives Federal Grants for Each of Its Active Research Programs - Total Exceeds $730K.
• Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial.
• Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company.
• Cellceutix Reports its Very Novel Anti-Cancer Agent, Kevetrin, at Dana Farber for Start of Clinical .
• Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin Has Begun.
• Cellceutix Responds to Public Support by Expediting Autism Studies - Completes Two Required Safety P.
• Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug.
• Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech.
• Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support; Company Continues to Advance Kevetrin.
• Cellceutix Signs Lab Services Research Support Agreement With Dana Farber-Partners CancerCare Inc. .
• Cellceutix Signs Manufacturing Agreement for Kevetrin Active Pharmaceutical Ingredient.
• Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug.
• Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug.
• Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs.
• Cellceutix's Drug Discovery Is a Major Leap Forward in the Fight Against Cancer.
• Cellceutixs KevetrinSlows Pancreatic Cancer Tumor Growth by 94 percent - Protocol Towards Clinical.
• CTIX Announces Lung Cancer Animal Model Testing Results with Kevetrin.
• Dr Paul Marks MD Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents .
• FDA Schedules Meeting With Cellceutix on New Psoriasis Drug.
• Insight Into Cellceutix Corporation's Breakthrough Cancer Compound.
• Interview w Biotech Stock Trader- Dr. Paul Ginsberg Joins Cellceutix Advisory Board.
• Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells.
• Kevetrin in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study.
• Kevetrin" Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer.
• Nearing Completion of Toxicity Studies for Its Cancer Compound for Resistant Lung and Breast Cancers.
• New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes.
• Press Release Audio 2-16-2010.
• Press Release Audio 3-29-2010.
• Prostate Cancer Joins Growing List of Cancers That Succumb to Kevetrin.
• Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound Pfizer and Novartis.
• Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer.
• Vendor Showcases Kevetrin (TM)- Anti-Cancer Drug at American Society for Mass Spectromet.
• With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug.